TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
B: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
C: N/A
D: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: TRK-100STP; Type: EXPERIMENTAL; Interventions: Drug: TRK-100STP high dose, Drug: TRK-100STP low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TRK-100STP high dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: TRK-100STP low dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Drug therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Medical therapy | Arm Label: Drug therapy + stenting angioplasty; Type: EXPERIMENTAL; Interventions: Procedure: stenting angioplasty plus medical therapy | Intervention Type: PROCEDURE; Name: stenting angioplasty plus medical therapy; Assigned to Arm(s): Drug therapy + stenting angioplasty | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Drug therapy
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: Experimental treatment strategy; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor, Drug: Acetylsalicylic Acid | Arm Label: Reference treatment strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ticagrelor, Drug: Acetylsalicylic Acid, Drug: Clopidogrel | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Experimental treatment strategy, Reference treatment strategy | Intervention Type: DRUG; Name: Acetylsalicylic Acid; Assigned to Arm(s): Experimental treatment strategy, Reference treatment strategy | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Reference treatment strategy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
B: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Alteplase Placebo + Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase Placebo, Drug: Aspirin | Arm Label: Alteplase + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Alteplase, Drug: Aspirin Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): Alteplase + Aspirin Placebo | Intervention Type: DRUG; Name: Alteplase Placebo; Assigned to Arm(s): Alteplase Placebo + Aspirin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Alteplase Placebo + Aspirin | Intervention Type: DRUG; Name: Aspirin Placebo; Assigned to Arm(s): Alteplase + Aspirin Placebo
D: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
C: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
D: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: Endeavor arm; Type: EXPERIMENTAL; Interventions: Device: Zotarolimus-eluting stent | Arm Label: Endeavor resolute arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Zotarolimus-eluting stent for ACS and DM | Arm Label: Xience arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent for long lesion | Arm Label: Cypher arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent for short lesion | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent; Assigned to Arm(s): Endeavor arm | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent for ACS and DM; Assigned to Arm(s): Endeavor resolute arm | Intervention Type: DEVICE; Name: Everolimus-eluting stent for long lesion; Assigned to Arm(s): Xience arm | Intervention Type: DEVICE; Name: Sirolimus-eluting stent for short lesion; Assigned to Arm(s): Cypher arm
B: Arm Label: ASS + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clopidogrel | Arm Label: ASS + Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): ASS + Placebo, ASS + Plavix
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: aspirin+placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: aspirin + placebo | Arm Label: aspirin+pregrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + pregrel (Clopidogrel resinate) | Arm Label: Aspirin+Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + plavix (Clopidogrel bisulfate) | Intervention Type: DRUG; Name: aspirin + pregrel (Clopidogrel resinate); Assigned to Arm(s): aspirin+pregrel | Intervention Type: DRUG; Name: aspirin + placebo; Assigned to Arm(s): aspirin+placebo | Intervention Type: DRUG; Name: aspirin + plavix (Clopidogrel bisulfate); Assigned to Arm(s): Aspirin+Plavix

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Arm Label: Aspirin; Type: N/A; Interventions: Drug: 100 mg enteric-coated aspirin | Arm Label: Placebo; Type: N/A; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 100 mg enteric-coated aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: Isosorbide Mononitrate XL (ISMN); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isosorbide Mononitrate XL (ISMN) | Arm Label: Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cilostazol | Arm Label: ISMN XL and Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: ISMN XL and Cilostazol | Arm Label: Neither ISMN nor cilostazol; Type: PLACEBO_COMPARATOR; Interventions: Other: Neither ISMN nor cilostazol | Intervention Type: DRUG; Name: Isosorbide Mononitrate XL (ISMN); Assigned to Arm(s): Isosorbide Mononitrate XL (ISMN) | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): Cilostazol | Intervention Type: DRUG; Name: ISMN XL and Cilostazol; Assigned to Arm(s): ISMN XL and Cilostazol | Intervention Type: OTHER; Name: Neither ISMN nor cilostazol; Assigned to Arm(s): Neither ISMN nor cilostazol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke
Brief Summary: The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in high-risk patients with TIA or minor stroke.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus
Brief Summary: The study is a prospective randomized study comparing safety and effectiveness of a basal-bolus regimen with glargine once daily and glulisine before meals, a basal plus regimen with glargine once daily and supplemental doses of glulisine, and sliding scale regular insulin (SSI) on correction of insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes.


Options:
A: Arm Label: sliding scale regular insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin | Arm Label: glargine insulin and glulisine insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glargine basal insulin and glulisine prandial insulin | Intervention Type: DRUG; Name: sliding scale regular insulin; Assigned to Arm(s): sliding scale regular insulin | Intervention Type: DRUG; Name: glargine basal insulin and glulisine prandial insulin; Assigned to Arm(s): glargine insulin and glulisine insulin
B: Arm Label: Bedtime supplementation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bedtime insulin Aspart (Novolog) | Arm Label: no bedtime supplementation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bedtime insulin Aspart (Novolog); Assigned to Arm(s): Bedtime supplementation
C: Arm Label: Basal Plus Regimen; Type: EXPERIMENTAL; Interventions: Drug: Basal Plus | Arm Label: Basal Bolus; Type: EXPERIMENTAL; Interventions: Drug: Basal Bolus | Arm Label: sliding scale regular insulin (SSRI); Type: ACTIVE_COMPARATOR; Interventions: Drug: sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: sliding scale regular insulin (SSRI); Assigned to Arm(s): sliding scale regular insulin (SSRI) | Intervention Type: DRUG; Name: Basal Bolus; Assigned to Arm(s): Basal Bolus | Intervention Type: DRUG; Name: Basal Plus; Assigned to Arm(s): Basal Plus Regimen
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, Drug: Insulin glulisine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Regular insulin | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Regular insulin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1

Answer: C